JS002 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 79 | Homozygous familial hypercholesterolemia | 1 |
79. Homozygous familial hypercholesterolemia
Clinical trials : 145 / Drugs : 114 - (DrugBank : 26) / Drug target genes : 8 - Drug target pathways : 17
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04515927 (ClinicalTrials.gov) | August 17, 2020 | 11/8/2020 | To Evaluate the Efficacy and Safety of JS002 in HoFH Patients | An Open-label, Single-arm Study Evaluated the Efficacy and Safety of JS002 in Patients With Homozygous Familial Hypercholesterolemia | Hyperlipemia | Drug: JS002 | Shanghai Junshi Bioscience Co., Ltd. | NULL | Active, not recruiting | 12 Years | 75 Years | All | 30 | Phase 2 | China |